PFIZER INC Restructuring and Related Cost, Incurred Cost
PFIZER INC (PFE) reported Restructuring and Related Cost, Incurred Cost of $967.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2020-11-05
- PFIZER INC restructuring and related cost, incurred cost for the quarter ending 2019-12-31 was $515.00M.
- PFIZER INC restructuring and related cost, incurred cost for the quarter ending 2019-09-29 was $420.00M.
- PFIZER INC restructuring and related cost, incurred cost for the quarter ending 2019-06-30 was -$60.00M.
- PFIZER INC restructuring and related cost, incurred cost for the quarter ending 2019-03-31 was $92.00M.
- PFIZER INC restructuring and related cost, incurred cost for fiscal 2019 was $967.00M, a 30.93% decline from fiscal 2018.
- PFIZER INC restructuring and related cost, incurred cost for fiscal 2018 was $1.40B.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month | Restructuring and Related Cost, Incurred Cost 66 month | Restructuring and Related Cost, Incurred Cost 69 month | Restructuring and Related Cost, Incurred Cost 72 month | Restructuring and Related Cost, Incurred Cost 75 month | Restructuring and Related Cost, Incurred Cost 78 month | Restructuring and Related Cost, Incurred Cost 81 month | Restructuring and Related Cost, Incurred Cost 84 month | Restructuring and Related Cost, Incurred Cost 87 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $515.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $935.00M derived: sum of 2 quarters · filed 2020-11-05 | $875.00M derived: sum of 3 quarters · filed 2020-11-05 | $967.00M 10-K · filed 2020-02-27 | ||||||||
| 2019-09-29 | $420.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $360.00M derived: sum of 2 quarters · filed 2020-11-05 | $452.00M 10-Q · filed 2020-11-05 | |||||||||
| 2019-06-30 | -$60.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $32.00M 10-Q · filed 2020-08-06 | ||||||||||
| 2019-03-31 | $92.00M 10-Q · filed 2019-05-09 | |||||||||||
| 2018-12-31 | $1.40B 10-K · filed 2019-02-28 | |||||||||||
| 2012-04-01 | $12.37B 10-Q · filed 2012-05-10 | |||||||||||
| 2011-12-31 | $11.66B 10-K · filed 2012-02-28 | |||||||||||
| 2011-10-02 | $11.07B 10-Q · filed 2011-11-10 | |||||||||||
| 2011-07-03 | $10.64B 10-Q · filed 2011-08-11 | |||||||||||
| 2011-04-03 | $504.00M derived: 10-Q 75 month − 10-K 72 month · filed 2011-05-12 | $1.04B derived: sum of 2 quarters · filed 2011-05-12 | $1.70B derived: sum of 3 quarters · filed 2011-05-12 | $10.31B 10-Q · filed 2011-05-12 | ||||||||
| 2010-12-31 | $541.00M derived: 10-K 72 month − 10-Q 69 month · filed 2011-02-28 | $1.20B derived: sum of 2 quarters · filed 2011-02-28 | $9.81B 10-K · filed 2011-02-28 | |||||||||
| 2010-10-03 | $658.00M derived: 10-Q 69 month − 10-Q 66 month · filed 2010-11-12 | $9.27B 10-Q · filed 2010-11-12 | ||||||||||
| 2010-07-04 | $8.61B 10-Q · filed 2010-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |